-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
-
Primary results for SOLSTICE and VISTA to be shared for the first time
Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.
More 2026 Scientific Sessions News
Scientific Sessions Newsmakers
-
Panel discussion to explore stem cell-derived beta cell therapy for type 1 diabetes
Sanjoy Dutta, PhD, Jay Skyler, MD, and other panelists will share insights on advances in the use of manufactured islets and what it might take to achieve widespread clinical use.
-
Trending topics in diabetes and obesity research and care highlight the 2026 Scientific Sessions program
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.
-
Discover New Orleans during the Scientific Sessions
Let the good times roll! A rich cultural character, exceptional culinary landscape, and vibrant musical traditions await in the city known as The Big Easy.
-
Standards of Care in Overweight and Obesity 2025 updates help optimize care for patients and clinicians
Louis J. Aronne, MD, DABOM, and Kim Gudzune, MD, MPH, led an overview of the newly developed guidance, which provides clinicians, researchers, policy makers, and others with the components of obesity care, general treatment goals, and tools to evaluate the quality of care.
-
Investigators spotlight innovative bioengineering efforts for beta cell replacement therapy
Michael R. Rickels, MD, MS, and others shared results from FORWARD-101, which studied an investigational stem cell-derived, fully differentiated islet cell therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemic events.